Personalized cancer therapy using a patient-derived tumor tissue xenograft model: A translational field worthy of exploring further?

Personalized Medicine

Volumn 7, Issue 5, 2010, Pages 597-606

  Jin, Ketao ^a   He, Kuifeng ^a   Li, Guangliang ^a   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

cancer; personalized cancer therapy; tumor model; xenograft

Indexed keywords

CETUXIMAB; CYCLOPHOSPHAMIDE; ERLOTINIB; FLUOROURACIL; GEFITINIB; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IRINOTECAN; MERCAPTOPURINE; PANITUMUMAB; TAMOXIFEN; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CANCER GENETICS; DISEASE MARKER; DRUG TARGETING; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; PERSONALIZED CANCER THERAPY; PRIORITY JOURNAL; REVIEW; TISSUE GRAFT; TREATMENT RESPONSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

EID: 77957553519     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.48     Document Type: Review

References (74)

1. Khoury MJ, Berg A, Coates R et al.: The evidence dilemma in genomic medicine. Health Aff (Millwood) 27, 1600-1611 (2008). • Important study of clinical application of molecular marker, HER2, in evaluation of efficacy and safety of trastuzumab.
2. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002). (Pubitemid 34111379)
3. Ross JS, Fletcher JA, Linette GP et al.: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8, 307-325 (2003).
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005). • Important study of clinical application of molecular marker, KRAS gene mutations, in patients with metastatic colorectal carcinoma to predict response to anti-EGF receptor monoclonal antibody therapy.
5. Allegra CJ, Jessup JM, Somerfield MR et al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
6. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568 (2005).
7. Eberhard DA, Johnson BE, Amler LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005). (Pubitemid 46300206)
8. Bell DW, Lynch TJ, Haserlat SM et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081-8092 (2005). (Pubitemid 46657411)
9. Goetz MP, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005). (Pubitemid 46260189)
10. Goetz MP, Suman VJ, Ingle JN et al.: A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res. 12, 2080-2087 (2006).
11. Jin Y, Desta Z, Stearns V et al.: CYP2D6 genotype, antidepressant use and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97, 30-39 (2005).
12. Massarweh S, Osborne CK, Creighton CJ et al.: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68, 826-833 (2008). (Pubitemid 351206760)
13. Overdevest JB, Theodorescu D, Lee JK: Utilizing the molecular gateway: the path to personalized cancer management. Clin. Chem. 55, 684-697 (2009).
14. van Schaik RH: CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist. Updat. 11, 77-98 (2008).
15. Ratain MJ: From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin. Cancer Res. 12, 1658-1660 (2006).
16. Maitland ML, Vasisht K, Ratain MJ: TPMT, UGTlAl and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol. Sci. 27, 432-437 (2006). (Pubitemid 44051569)
17. Iyer L, King CD, Whitington PF et al.: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101, 847-854 (1998). (Pubitemid 28096082)
18. Schwab M, Zanger UM, Marx C et al.: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26, 2131-2138 (2008).
19. Wei X, Elizondo G, Sapone A et al.: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51, 391-400 (1998). (Pubitemid 28413205)
20. van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1 G>A mutation. Int. J. Cancer 101, 253-258 (2002). (Pubitemid 34970893)
21. Yen JL, McLeod HL: Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer 43, 1011-1016 (2007).
22. Marsh S: Thymidylate synthase pharmacogenetics. Invest. New Drugs 23, 533-537 (2005). (Pubitemid 43162472)
23. Etienne-Grimaldi MC, Francoual M, Formento JL, Milano G: Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics 8, 1561-1566 (2007). (Pubitemid 350286400)
24. Sadee W, Dai Z: Pharmacogenetics/genomics and personalized medicine. Hum. Mol. Genet. 14, R207-R214 (2005). (Pubitemid 41631889)
25. Petros WP, Evans WE: Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol. Sci. 25, 457-464 (2004).
26. Yong WP, Innocenti F: Translation of pharmacogenetic knowledge into cancer therapeutics. Clin. Adv. Hematol. Oncol. 5, 698-706 (2007). (Pubitemid 351699413)
27. Stanulla M, Schaeffeler E, Flohr T et al.: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293, 1485-1489 (2005). (Pubitemid 40393293)
28. McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3, 89-98 (2002). (Pubitemid 34285242)
29. Schaeffeler E, Fischer C, Brockmeier D et al.: Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407-417 (2004). (Pubitemid 38971231)
30. van den Akker-van Marle ME, Gurwitz D, Detmar SB et al.: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7, 783-792 (2006). (Pubitemid 44225913)
31. Hartford CM, Dolan ME: Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 8, 1159-1168 (2007). (Pubitemid 47578225)
32. Zhou S: Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr. Clin. Pharmacol. 1, 119-128 (2006).
33. Davies SM: Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet? Hematology Am. Soc. Hematol. Educ. Program. 111-117 (2006).
34. Krause DS, van Etten RA: Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005). (Pubitemid 41058349)
35. Druker BJ. David A: Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J. Clin. Oncol. 21, 239S-245S (2003).
36. Druker BJ, Talpaz M, Resta DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001). • • Important study of preclinical predicting tumor response to anticancer therapy using patient-derived human tumor tissue (PDTT) xenograft model. (Pubitemid 32267972)
37. Rubio-Viqueira B, Jimeno A, Cusatis G et al.: An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652-4661 (2006). • Studies supporting the achievements of genomic and proteomic molecular markers for personalized cancer therapy. (Pubitemid 44297818)
38. Pusztai L: Current status of prognostic profiling in breast cancer. Oncologist 13, 350-360 (2008). (Pubitemid 351679913)
39. Potti A, Dressman HK, Bild A et al.: Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12, 1294-1300 (2006). (Pubitemid 44706932)
40. Koomen JM, Haura EB, Bepler G et al.: Proteomic contributions to personalized cancer care. Mol. Cell Proteomics 7, 1780-1794 (2008). • Studies revealing the limitations of genomic, and proteomic molecular markers for personalized cancer therapy.
41. Lusa L, McShane LM, Reid JF et al.: Challenges in projecting clustering results across gene expression-profiling datasets. J. Natl. Cancer Inst. 99, 1715-1723 (2007). (Pubitemid 351767219)
42. Brenton JD, Carey LA, Ahmed AA, Caldas C: Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J. Clin. Oncol. 23, 7350-7360 (2005). (Pubitemid 46202348)
43. Johnson JI, Decker S, Zaharevitz D et al.: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001). (Pubitemid 32522115)
44. Sausville A, Burger AM: Contribution of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351-3354 (2006).
45. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337 (2004). • • Important study of preclinical predicting tumor response to anticancer therapy using a PDTT xenograft model.
46. Huynh H, Soo KC, Chow PK et al.: Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin. Cancer Res. 12, 4306-4314 (2006).
47. Cutz JC, Guan J, Bayani J et al.: Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin. Cancer Res. 12, 4043-4054 (2006). (Pubitemid 44078092)
48. Visonneau S, Cesano A, Torosian MH, Santoli D: Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Clin. Cancer Res. 3, 1491-1500 (1997). •• Important study of predicting preclinical tumor response to anticancer therapy using a PDTT xenograft model. (Pubitemid 27431555)
49. Marangoni E, Vincent-Salomon A, Auger N et al.: A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13, 3989-3998 (2007). (Pubitemid 47037607)
50. Loukopoulos P, Kanetaka K, Takamura M et al.: Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29, 193-203 (2004). (Pubitemid 39304976)
51. Press JZ, Kenyon JA, Xue H et al.: Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol. Oncol. 110, 256-264 (2008).
52. Boven E, Winograd B, Berger DP et al.: Phase II preclinical drug screening in human tumor xenografts: a first European mu lticenter collaborative study. Cancer Res.
53. 52, 5940-5947 (1992).
54. Hammer S, Sommer A, Fichtner I et al.: Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin. Cancer Res. 16, 1452-1465 (2010).
55. Rajeshkumar NV, Tan AC, De Oliveira E et al.: Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 15, 4138-4146 (2009).
56. Maris JM, Courtright J, Houghton PJ et al.: Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 581-587 (2008). (Pubitemid 351155829)
57. Huynh H, Chow PK, Palanisamy N et al.: Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J. Hepatol. 49, 52-60 (2008).
58. Wang Z, Zhou J, Fan J et al.: Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 14, 5124-5130 (2008).
59. Houghton PJ, Morton CL, Tucker C et al.: The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer 49, 928-940 (2007). (Pubitemid 350022448)
60. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM: The tumor microenvironment: a critical determinant of neoplastic evolution. Eur. J. Cell Biol. 82, 539-548 (2003).
61. Shu Q, Wong KK, Su JM et al.: Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells 26, 1414-1424 (2008).
62. Verschraegen CF, Hu W, Du Y et al.: Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin. Cancer Res. 9, 845-852 (2003). (Pubitemid 36182623)
63. Schmidt KF, Ziu M, Schmidt NO et al.: Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J. Neurooncol. 68, 207-215 (2004). (Pubitemid 38878254)
64. Verstijnen CP, Arends JW, Moerkerk P et al.: Culturing and xenografting of primary colorectal carcinoma cells: comparison of in vitro, and in vivo model and primary tumor. Anticancer Res. 8, 1193-1200 (1988). (Pubitemid 19045902)
65. Whiteford CC, Bilke S, Greer BT et al.: Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 67, 32-40 (2007). (Pubitemid 46142757)
66. Wei JS, Greer BT, Westermann F et al.: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 64, 6883-6891 (2004). (Pubitemid 39330995)
67. Son CG, Bilke S, Davis S et al.: Database of mRNA gene expression profiles of multiple human organs. Genome Res. 15, 443-450 (2005). (Pubitemid 40467786)
68. Khanna C, Khan J, Nguyen P et al.: Metastasis associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 61, 3750-3759 (2001). (Pubitemid 32694989)
69. Kelland LR: Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer. 40, 827-836 (2004).
70. Visonneau S, Cesano A, Torosian MH et al.: Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am. J. Pathol. 152, 1299-1311 (1998). (Pubitemid 28221882)
71. Clarke R: Animal models of breast cancer: their diversity and role in biomedical research. Breast Cancer Res. Treat. 39, 1-6 (1996). (Pubitemid 26136499)
72. Fingert HJ, Chen Z, Mizrahi N et al.: Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay. Cancer Res. 47, 3824-3829 (1987). (Pubitemid 17105733)
73. Hoehn W, Schroeder FH, Reimann JF et al.: Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82). Prostate 1, 95-104 (1980). (Pubitemid 11016689)
74. Cespedes MV, Casanova I, Parreno M, Mangues R: Mouse models in oncogenesis and cancer therapy. Clin. Transl. Oncol. 8, 318-329 (2006).